IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
Crunchbase Investment Rounds
|Date||Amount||Round||Valuation||Lead Investor||Other Investors|
|2016-01-05||$11,827,600||Series A||Lundbeckfonden Ventures||Novo Nordisk|